A comparative effectiveness study examined whether primary cytoreductive surgery or neoadjuvant chemotherapy produces longer survival rates in patients with high-grade serous ovarian carcinoma.

News

Statin use following an ovarian cancer diagnosis is associated with improved survival in patients with the disease.
Three recent studies have identified trends in survival for patients with ovarian, colon, and breast cancer in the United States based on race and disease stage.

A recent study found that treatment with PARP inhibitors significantly increases the risk of hematologic toxicities and warrants frequent clinical monitoring by clinicians.

Read More

The Institute for Clinical and Economic Review (ICER) confirmed in a recent report that evidence is lacking for outcomes comparisons of ploy-ADP ribose polymerase (PARP) inhibitors to treat ovarian cancer, and that prices should be lowered to increase affordability and patient access.

Read More

Research in Review

Though proven to offer superior outcomes versus other treatment regimens, less than half of patients receive standard of care for locally advanced cervical cancer, according to a study published in Gynecologic Oncology.

Read More

In a study published in JAMA Oncology, researchers a found that, after adjusting for changes in screening, there was a decrease in all-grade cervical intraepithelial neoplasia (CIN), a known link to cervical cancer, among women 15-19 years old who received the human papillomavirus (HPV) vaccine.   

Read More

Primary cytoreductive surgery (PCS) may improve survival for patients with stage III ovarian cancer, while neoadjuvant chemotherapy may be the optimal treatment for patients with stage IV disease, reported researchers in the Journal of Clinical Oncology, who examined the use and effectiveness of neoadjuvant chemotherapy in clinical practice.

Read More

Administering immunotherapy immediately after chemotherapy may improve response when treating patients with stage IIIC-IV tubo-ovarian high-grade serous carcinoma, according to findings from a study published in Clinical Cancer Research.

Read More

Subscribe to Ovarian Cancer